EP0946178A4 - Combination therapy for reducing the risks associated with cardiovascular disease - Google Patents

Combination therapy for reducing the risks associated with cardiovascular disease

Info

Publication number
EP0946178A4
EP0946178A4 EP97941644A EP97941644A EP0946178A4 EP 0946178 A4 EP0946178 A4 EP 0946178A4 EP 97941644 A EP97941644 A EP 97941644A EP 97941644 A EP97941644 A EP 97941644A EP 0946178 A4 EP0946178 A4 EP 0946178A4
Authority
EP
European Patent Office
Prior art keywords
reducing
combination therapy
cardiovascular disease
risks associated
risks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97941644A
Other languages
German (de)
French (fr)
Other versions
EP0946178A1 (en
Inventor
Robert J Gould
Steven A Nichtberger
Patricia A Rhymer
Lars Olofsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621970.4A external-priority patent/GB9621970D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0946178A1 publication Critical patent/EP0946178A1/en
Publication of EP0946178A4 publication Critical patent/EP0946178A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97941644A 1996-09-18 1997-09-15 Combination therapy for reducing the risks associated with cardiovascular disease Withdrawn EP0946178A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2658196P 1996-09-18 1996-09-18
US26581P 1996-09-18
GBGB9621970.4A GB9621970D0 (en) 1996-10-22 1996-10-22 Combination therapy for reducing the risks associated with cardiovascular disease
GB9621970 1996-10-22
PCT/US1997/016388 WO1998011896A1 (en) 1996-09-18 1997-09-15 Combination therapy for reducing the risks associated with cardiovascular disease

Publications (2)

Publication Number Publication Date
EP0946178A1 EP0946178A1 (en) 1999-10-06
EP0946178A4 true EP0946178A4 (en) 2003-05-07

Family

ID=26310268

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97941644A Withdrawn EP0946178A4 (en) 1996-09-18 1997-09-15 Combination therapy for reducing the risks associated with cardiovascular disease

Country Status (5)

Country Link
EP (1) EP0946178A4 (en)
JP (1) JP2001500875A (en)
AU (1) AU723315B2 (en)
CA (1) CA2265827A1 (en)
WO (1) WO1998011896A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
JP4588877B2 (en) 1998-06-17 2010-12-01 ブリストル−マイヤーズ スクイブ カンパニー Prevention of cerebral infarction by combined administration of ADP-receptor antiplatelet substance and antihypertensive drug
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
SE9802973D0 (en) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
DK1176956T3 (en) * 1999-05-07 2008-05-26 Encysive Pharmaceuticals Inc Carboxylic acid derivatives which inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
DK1272220T4 (en) * 2000-04-10 2016-11-28 Nicholas John Wald Cardiovascular disease prevention formulation
US20020048599A1 (en) * 2000-10-20 2002-04-25 Thomas H. Mueller Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation
DE10129725A1 (en) 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2004080488A2 (en) * 2003-03-10 2004-09-23 Bayer Healthcare Ag Combined preparations of acetyl salicylic acid with an hmg-coa reductase inhibitor
GB0306615D0 (en) * 2003-03-22 2003-04-30 Astrazeneca Ab New use
GB0307715D0 (en) 2003-04-03 2003-05-07 Ethicon Endo Surgery Inc Guide wire structure for insertion into an internal space
US8070693B2 (en) 2004-09-30 2011-12-06 Cook Medical Technologies Llc Articulating steerable wire guide
US7598233B2 (en) * 2005-03-28 2009-10-06 Kowa Co., Ltd. Method for treating thrombosis
ES2378896T3 (en) 2005-09-15 2012-04-18 Otsuka Pharmaceutical Co., Ltd. Combination of drugs containing Probucol and a tetrazolyl alkoxy dihydrocarbostiryl derivative with superoxide inhibitory effects
US8715205B2 (en) 2006-08-25 2014-05-06 Cook Medical Tecnologies Llc Loop tip wire guide
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
LV14963B (en) 2013-06-28 2015-10-20 Tetra, Sia Corrector of endothelial dysfunction
EP4403138A3 (en) 2015-05-01 2024-10-09 JenaValve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281585A (en) * 1991-05-07 1994-01-25 Merck & Co., Inc. Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
WO1997038694A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5281585A (en) * 1991-05-07 1994-01-25 Merck & Co., Inc. Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets
WO1997038694A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ARRIGONI-MARTELLI E: "FIRST EUROPEAN CONGRESS OF PHARMACOLOGY", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 31, no. 8, December 1995 (1995-12-01), pages 635 - 637, XP001061459, ISSN: 0025-7656 *
CASTAIGNE A ET AL: "TRAITEMENT MEDICAL DES PATIENTS AYANT UN ANGOR STABLE", REVUE DU PRATICIEN, J.B. BAILLERE, PARIS, FR, vol. 45, no. 17, 1975, pages 2161 - 2167, XP001061466, ISSN: 0035-2640 *
MALYSZKO JOLANTA ET AL: "Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotonergic system and serum lipids in Japanese monkeys.", THROMBOSIS RESEARCH, vol. 81, no. 3, 1996, pages 397 - 402, XP002233543, ISSN: 0049-3848 *
NOTARBARTOLO A ET AL: "INHIBITION OF THROMBOXANE BIOSYNTHESIS AND PLATELET FUNCTION BY SIMVASTATIN IN TYPE IIA HYPERCHOLESTEROLEMIA", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, XX, XX, vol. 15, no. 2, February 1995 (1995-02-01), pages 247 - 251, XP001037365, ISSN: 1079-5642 *
See also references of WO9811896A1 *
TANVEER RAB S ET AL: "CORONARY ANEURYSMS AFTER STENT PLACEMENT: A SUGGESTION OF ALTERED VESSEL WALL HEALING IN THE PRESENCE OF ANTI-INFLAMMATORY AGENTS", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, XX, XX, vol. 18, no. 6, 15 November 1991 (1991-11-15), pages 1524 - 1528, XP001083633, ISSN: 0735-1097 *
ZHANG L-H ET AL: "THE CHIRAL SPECIFIC SYNTHESIS OF DMP 754, A PLATELET GP IIB/IIIA ANTAGONIST", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 37, no. 26, 1996, pages 4455 - 4458, XP002071215, ISSN: 0040-4039 *

Also Published As

Publication number Publication date
AU4350897A (en) 1998-04-14
CA2265827A1 (en) 1998-03-26
AU723315B2 (en) 2000-08-24
EP0946178A1 (en) 1999-10-06
WO1998011896A1 (en) 1998-03-26
JP2001500875A (en) 2001-01-23

Similar Documents

Publication Publication Date Title
EP0904082A4 (en) Combination therapy for reducing the risks associated with cardiovascular disease
EP0946178A4 (en) Combination therapy for reducing the risks associated with cardiovascular disease
EG24678A (en) Combination therapy
EP0879279A4 (en) Diabetes therapy
AP2002002661A0 (en) Combination therapy for oesteoporosis
ZA987843B (en) Combination therapy.
IL127306A0 (en) Combination therapy
EP1024696A4 (en) Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease
GB9421930D0 (en) The barpress
GB9601062D0 (en) The updrifter
GB9612082D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9621970D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9616804D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9603545D0 (en) The spraymate
ZA977005B (en) Therapeutic uses
GB9617526D0 (en) The hand shield
EG21150A (en) The egtptian lithotriptor k h j
GB9605466D0 (en) Therapy
GB9605525D0 (en) Therapy
GB9611121D0 (en) The mirrormaker
GB9602510D0 (en) The easythrow fetchball
GB9626734D0 (en) The jetlift
GB9602199D0 (en) The seducterlens
GB9614951D0 (en) The carrynet
GB9613369D0 (en) The Susean

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030326

17Q First examination report despatched

Effective date: 20040310

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050825